AAX Biotech strengthens the team with new Senior Manager of Science & Development
AAX Biotech announces the appointment of Juan Astorga-Wells as new Senior Manager of Science & Development. This significant recruitment underscores the company's commitment to advancing its technologies that aim to produce better and more effective antibody-based medicines.
AAX Biotech is a Swedish startup biotech company aiming to solve unmet needs in developing next-generation antibody therapeutics. The company’s two unique and patentable technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market.
Juan Astorga-Wells, Ph.D. in Medical Biochemistry from Karolinska Institutet, joins AAX Biotech bringing a unique blend of academic and entrepreneurial expertise. His impressive publication record in highly recognized scientific journals demonstrates his extensive bioanalytical knowledge. As a co-founder of three biotech companies and the holder of several patents, Juan Astorga-Wells has a proven track record in translating scientific innovation into market-ready solutions. His specialized skills in epitope mapping are instrumental for AAX Biotech's focus on advancing its two unique and patentable technologies, Seqitope™ and Opti-mAb™. With over 15 years of managerial experience in the bioanalytical sector and a customer-centric approach, Juan Astorga-Wells is well-equipped to lead and innovate, meeting market demands effectively.
"I am excited to join AAX and contribute to advancing our innovative technologies. I believe that AAX's state-of-the-art, high-throughput discovery platform will bring the next generation of epitope mapping and novel antibody types to the market. Our proprietary technologies promise to significantly advance the field and provide unprecedented opportunities for innovation in immunotherapy. This role represents a unique opportunity to blend scientific innovation with real-world applications, and I'm eager to drive these advancements forward at AAX,” says Juan Astorga-Wells.
Juan Astorga-Wells will play a crucial role in advancing AAX Biotech’s cutting-edge technologies for further innovation. Simultaneously, Juan Astorga-Wells will actively engage in cultivating lasting partnerships and collaborations, thereby contributing significantly to the company’s sustained growth and success.
"The addition of Juan to our team represents a key milestone for AAX. His combination of technical know-how and forward-thinking leadership is set to elevate our technologies to new heights of innovation and market success. Juan's contribution is essential as we strive for scientific excellence and leadership in the bioanalytical market," says Maria Lisa Knudsen, CEO of AAX Biotech.
For more information, please contact:
Maria Lisa Knudsen, CEO
+46 72 939 5018
maria.knudsen@aaxbiotech.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
